Global Head and Neck Cancer Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027
“Global Head and Neck Cancer Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2027” is a recent report generated by MarketResearch.biz, which offers in-depth insights, revenue details, and other vital information regarding the global head and neck cancer market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global head and neck cancer market report has been segmented on the basis of drug class, distribution channel, and region.
Cancer is a disease of the cells, which are the body’s basic building blocks. Head and neck cancer is a group of cancers that starts in the mouth, nose, throat, larynx, sinuses, or salivary glands of human body. Head and neck squamous cell carcinoma (HNSCC) that comprising upper aerodigestive tract anatomic sites represents the third common cause of cancer death in worldwide. The use of surgery, radiation, and/or chemotherapy depends on tumor respectability and location.
Key factors expected to drive growth of the global head and neck cancer market is increasing patient foothold suffering from head and cancer. In addition, increasing healthcare expenditure, growing geriatric population, technological advancement in medical facilities, growing prevalence of chronic disease are among some other factors expected to drive growth of the global head and neck cancer market. Furthermore, rising products approval by health regulatory authority, increasing government initiative, growing pharmaceutical industry are among the other factors expected to drive growth of the target market over the forecast period. However, string regulatory rule may and high cost of treatment is expected to hamper the growth of the global target market to a certain extent in the forecasted years.
Major players are focusing on mergers and acquisitions, rising number of collaborations and partnerships with other player, in order to develop new novel products. Established players are partnering with other local player in order to form effective distribution network across the globe. These are the trends witnessed in the global head and neck cancer market, currently. For instance, in November 2016, Bristol-Myers Squibb received the FDA approval for Opdivo (nivolumab) for intravenous treatment of individuals with metastatic squamous cell carcinoma of the head and neck (SCCHN). According to the 2014 statistics by the World Health Organization (WHO), the annual occurrence rate of head and neck cancer is more than 550,000 cases with nearly 300,000 deaths each year, worldwide.
The market in North America is expected to dominate the global head and neck cancer market. This is primarily attribute to rising number of cases of chronic diseases, growing geriatric population, high healthcare expenditure, developed medical facilities in countries in the region. In contrast, the market in Asia Pacific is expected to be an emerging market for the global head and neck cancer market, and is expected to register highest CAGR in during the forecasted period, owing to developing healthcare infrastructure and rising healthcare expenditure in the region. Moreover, the markets in Europe, Latin America and Middle East & Africa are expected to register moderate growth revenue in the global head and neck cancer market over the forecast period.
GLOBAL HEAD AND NECK CANCER MARKET SEGMENTATION:
Segmentation by drug class:
- EGFR Inhibitors
- Mitotic Inhibitors
- Anti-PD-1 Monoclonal Antibodies
- Others (includes Docetaxel, fluorouracil (5FU), etc.)
Segmentation by distribution channel:
- Hospitals Pharmacies
- Retail Pharmacies
Segmentation by region:
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Particular Scope Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- South Africa
- Rest of Middle East and Africa
Actual Year 2017 Estimated Year 2018 Forecast Period 2018–2027 Revenue in US$
- Sanofi S.A.
- Pfizer Inc.
- Eli Lilly and Company
- Merck KgaA
- Bristol-Myers Squibb Company
- Bayer AG
- Galera Therapeutics, Inc.
- Fresenius KabiOncology Limited
- Teva Pharmaceutical Industries Ltd.
- AB Science SA
Request for TOC
Request for Customization
Don't just take our word. We are trusted by these great companies!